Ovid therapeutics Inc

14. Sept. 2026, 20:08 UTC

Ovid Therapeutics Inc is higher as it advances mid-stage development of OV329 and initiates multiple clinical studies. Topline data for OV329 is expected by late 2026.

11. Sept. 2026, 19:26 UTC

H.C. Wainwright raised Ovid Therapeutics' price target to $5.00, maintaining a Buy rating, contributing to positive sentiment as shares trade higher since Thursday's close.

9. Sept. 2026, 19:46 UTC

Ovid Therapeutics Inc shares are lower amid rising crude oil prices above $100, raising inflation concerns that may affect monetary policy.

8. Sept. 2026, 23:52 UTC

Ovid Therapeutics Inc is higher in after-market trading, reflecting positive momentum since Tuesday's close and positioning above its 20-day moving average.

1. Sept. 2026, 20:09 UTC

Ovid Therapeutics Inc is higher today, recovering from an early dip amid broader market dynamics and rising oil prices fueling inflation concerns.

31. Aug. 2026, 23:01 UTC

Ovid Therapeutics Inc shares are higher in after-market trading, moving from a low of 0.19% to a high of 4.69%.

28. Aug. 2026, 20:07 UTC

Ovid Therapeutics Inc shares are lower today amid rising U.S. Treasury yields and broader market declines. The stock saw notable volatility earlier in the session.

24. Aug. 2026, 19:16 UTC

Ovid Therapeutics Inc shares are higher today, recovering from an earlier dip. The stock remains above its 20-day moving average and last month's price.

21. Aug. 2026, 19:46 UTC

Ovid Therapeutics Inc is trading higher, maintaining a position near its one-month range. Shares pulled back earlier in the session but are advancing overall.

20. Aug. 2026, 23:31 UTC

Ovid Therapeutics Inc shares are higher in after-market trading, reflecting a significant shift in momentum since Thursday's close. No specific news was identified.

19. Aug. 2026, 21:21 UTC

Ovid Therapeutics shares declined in after-market trading, finishing near the day's low after peaking earlier in the session. The stock remains above its 20-day moving average.

14. Aug. 2026, 19:53 UTC

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13. Aug. 2026, 19:16 UTC

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12. Aug. 2026, 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7. Aug. 2026, 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6. Aug. 2026, 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5. Aug. 2026, 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4. Aug. 2026, 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3. Aug. 2026, 19:11 UTC

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31. Juli 2026, 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27. Juli 2026, 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22. Juli 2026, 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20. Juli 2026, 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.